Axon growth potential is highest in young neurons but diminishes with age, thus becoming a significant obstacle to axonal regeneration after injury in maturity. The mechanism for the decline is incompletely understood, and no effective clinical treatment is available to rekindle innate growth capability. Here, we show that Smad1-dependent bone morphogenetic protein (BMP) signaling is developmentally regulated and governs axonal growth in dorsal root ganglion (DRG) neurons. Down-regulation of the pathway contributes to the age-related decline of the axon growth potential. Reactivating Smad1 selectively in adult DRG neurons results in sensory axon regeneration in a mouse model of spinal cord injury (SCI). Smad1 signaling can be effectively manipulated by an adenoassociated virus (AAV) vector encoding BMP4 delivered by a clinically applicable and minimally invasive technique, an approach devoid of unwanted abnormalities in mechanosensation or pain perception. Importantly, transected axons are able to regenerate even when the AAV treatment is delivered after SCI, thus mimicking a clinically relevant scenario. Together, our results identify a therapeutic target to promote axonal regeneration after SCI.
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intrinsic axon growth capacity | intrathecal viral vector delivery S pinal cord injury (SCI) disrupts long-projection axons, with devastating neurological outcomes, yet no effective clinical treatment exists. Neurons fail to regenerate axons because of a growth-inhibiting environment at the injury site (1-4) and because of an age-dependent decline in the intrinsic axon growth potential (5, 6) . Nevertheless, blocking extracellular inhibitory molecules (7) (8) (9) (10) or alleviating the intracellular negative regulators of axonal growth (5, 6, 11, 12) enables only limited axonal regeneration. Thus, additional molecular pathways that can rekindle innate growth capability must exist but remain unidentified (13) .
Dorsal root ganglion (DRG) neurons are a favored model system to study axonal regeneration. These neurons have an axon with two branches-a peripheral branch that innervates sensory organs and a central branch that relays information to the CNS. The central branches of adult DRG neurons in the spinal cord are refractory to regeneration unless their peripheral branches are severed first. This so-called "conditioning lesion" paradigm activates a transcription program that enhances the intrinsic axonal growth potential (14) . Previously, through gene expression profiling, we have demonstrated that Smad1 is induced after peripheral axotomy and that intraganglionic delivery of bone morphogenetic protein 2 or 4 (BMP2 or -4) activates Smad1 and enhances the axon growth potential of adult DRG neurons in cultures. In contrast, severing the central branches of DRGs fails to activate the Smad1 pathway, which correlates with the absence of regeneration after SCI (15) .
These results suggested a possible involvement of Smad1 in regulating the growth state of DRG neurons. It is not known, however, whether Smad1 governs the axon growth program in young neurons and whether down-regulation of this pathway underlies the age-related decline of the intrinsic axon growth potential. Furthermore, it remains to be determined whether failure to reactivate Smad1 contributes to a lack-of-growth state after SCI and whether empowering older neurons with increased Smad1 signaling can promote axon regeneration after SCI in vivo. Here we show that Smad1-dependent BMP signaling is developmentally regulated and governs axon growth potential and that activating Smad1 in adult DRG neurons by adeno-associated virus (AAV)-BMP enhances regrowth of adult sensory axons in vivo.
Results

Smad1 Is Developmentally Regulated in DRG Neurons and Governs
Axon Growth Potential. Smads are the intracellular mediators of the TGF-β/BMP signaling pathway. TGF-β/BMP ligands activate receptor serine/threonine kinases, which in turn signal through C-terminal phosphorylation of Smads, leading to nuclear translocation of pSmads. Smad1, -5, and -8 mediate signaling of members of the BMP subfamily (16) . We first examined whether Smad1 is expressed in embryonic DRG neurons during the period of active axon growth. In situ hybridization of embryonic spinal cord showed that Smad1 was strongly expressed in the embryonic day (E)12.5 spinal cord and DRGs (Fig. 1A) . In contrast, Smad5 transcripts were mostly detected in the periventricular zone of the developing spinal cord, whereas Smad8 was expressed at low level in E12.5 DRGs (Fig. S1A) . Thus, Smad1 seems to be the dominant Smad that mediates BMP signaling in developing DRG neurons. We also examined Smad2, a mediator of the TGF-β subfamily, and found less-abundant expression level in E12.5 DRGs (Fig. S1A) .
We next conducted a time course analysis. Smad1 started to be expressed in DRGs at E10.5 and persisted through E15.5 (Fig.  S1B) . Consistent with its role as a transcription factor, we found abundant phosphorylated Smad1 (pSmad1) in the nuclei of embryonic DRG neurons by immunohistochemistry ( Fig. 1E and Fig.  S1C ). In contrast, in adult DRG neurons, pSmad1 is down-regulated ( Fig. 1F ) but reappears after a conditioning lesion (Fig. 1G ) (15) . The dynamic expression pattern of pSmad1 coincides with the changes of the intrinsic axon growth potential: embryonic and conditioned adult DRG neurons were able to extend much longer axons than adult naïve neurons in dissociated cultures ( Fig. 1 B-D and H) . pSmad1 was also found in the nuclei of motor neurons in the developing spinal cord and facial nucleus, as wells as in Purkinje, retinal ganglionic, and olfactory mitral cells (Fig. S1 C-G) , suggesting that it might also be involved in axonogenesis of other classes of neurons.
To test the model that a high level of BMP/Smad1 signaling contributes to the robust growth potential in embryonic neurons, we took advantage of a selective small-molecule inhibitor of type I BMP receptor kinases, dorsomorphin (DM) (17) . In E12.5 DRG explant cultures, DM strongly inhibited axon growth in a dose-dependent fashion ( Fig. 1 I and J) . The effect seemed to In dissociated neuronal cultures of E12.5 DRG grown on fibronectin, at 1 d in vitro, axon-bearing neurons (arrow) all had nuclear pSmad1 (red), whereas neurons that had not extended axons did not. BMP7 (2 μg/mL) increased the pSmad1 in the nuclei (O), axonal length (Q), and the percentage of axon-bearing neurons (P). Tuj1 stains entire neurons. *P < 0.05, ***P < 0.0001; one-way ANOVA followed by Bonferroni's post hoc test.
(Scale bars, 25 μm in K, Lower, and O; 50 μm in M; 100 μm in B-G and K, Upper; and 500 μm in A and I.) be cell autonomous: neurons in low-density dissociated cultures showed a similar dose-dependent inhibition (Figs. 1 K and L). When BMP signaling was blocked, growth-associated protein 43 (GAP-43), a marker for active axon growth, was significantly decreased (Fig. S2F) , and growth cones appeared dystrophic (Fig. 1K ). BMP signaling is not only essential for axonogenesis of peripheral nervous system (PNS) neurons, it also seems to be indispensible for neurite outgrowth of CNS neurons. Embryonic day 18.5 hippocampal neurons could not initiate or maintain neurite outgrowth in explant cultures in the absence of BMP signaling (Fig. S2 G-M) . Neuronal survival was not affected, because axons resumed growth after DM washout (Fig. S2N) . To further confirm that it is the canonical Smad1-dependent BMP pathway that is critical for axon growth, we knocked down Smad1 by RNAi in E12.5 DRG neurons and found that the axonal growth capacity was severely inhibited, an effect that could be rescued by an RNAi-resistant Smad1 construct ( Fig. 1 M and N) . In contrast, stimulation by exogenous BMP led to a further increase in the nuclear accumulation of pSmad1 and concurrent enhancement of axon growth potential ( Fig. 1 O-Q).
BMP/Smad1 Signaling Is Essential for the Conditioning Effect in Adult DRG Neurons. We next asked whether the conditioning effect in adult DRG neurons is based on reactivation of Smad1. Dissociated adult DRG neurons start to extend axons after a 1-d delay, representing an in vitro conditioning process, because the dissociation step severs peripheral axons. When BMP signaling was blocked by DM treatment immediately after plating, the initiation of axonal outgrowth of the dissociated DRG neurons was significantly inhibited, whereas neuronal survival was not affected because axons resumed growth after DM washout ( Fig. 2 A and B) . In support of a Smad1-dependent BMP signaling cascade that governs axon outgrowth, a time course study revealed a lag time of ≈9 h between the addition of DM and the arrest of axon outgrowth (Fig. 2C ). This lag time suggests that BMP signaling operates through a change on the transcriptional level, whereas an effect through LIM kinase-mediated local cytoskeletal stability seems less likely (18, 19) . Indeed, DM did not cause an acute collapse of growth cones; rather, a depletion of pSmad1 in nuclei was observed (Fig. 2D) . A delayed response to DM inhibition was also observed in dissociated DRG neurons that were conditioned in vivo by sciatic nerve transection. These in vivo conditioned DRG neurons were able to initiate but not maintain axon growth in cultures ( Fig. 2 E and F), suggesting that the downstream effectors controlling the axon growth capacity were already operational at the beginning owing to the conditioning lesion but required a sustained BMP signaling cascade to maintain their expression. Smad1 knockout mice are early-embryonically lethal because of defects in allantois development (20); we thus bred mutant mice with Smad1 loxP alleles (21) to the Wnt1-Cre line (22) to generate Smad1 conditional knockout (CKO) mice. DRG neurons from Smad1 flox/-; Wnt-1 Cre mice had no detectable Smad1 (Fig. 2I) ; by comparison, abundant Smad1 was seen in DRG neurons from Smad1 flox/+ ; Wnt-1 Cre control littermates (Fig. 2I ). When DRG neurons from the Smad1 CKO mice were cultured, they displayed markedly decreased capability to initiate or maintain axonal extension ( Fig.  2 G and H) . These results support a model in which reactivation of the Smad1-dependent BMP pathway is critical for rekindling the innate growth potential in adult sensory neurons.
In Vivo Activation of Smad1 Enhances the Axon Growth Potential of Adult DRG Neurons. We then set out to test whether in vivo activation of Smad1 in adult DRG neurons could promote sensory axon regeneration in a rodent SCI model. We designed an AAVbased strategy, coupled with a clinically applicable and minimally invasive delivery method. We reasoned that delivering AAV directly into the lumbar cerebrospinal fluid space would lead to widespread distribution of the viruses to target multilevel DRGs. DRGs reside at the end of nerve root sleeves surrounded by cerebrospinal fluid-providing the basis for intrathecal delivery (Fig. 3A) . Intrathecal AAV-GFP injection led to high and selective transduction of DRG neurons (up to 50% in lumbosacral, 12% in thoracic, and 30% in cervical DRGs) ( Fig. 3B and Fig. S3  A and B) . GFP was well visualized within individual axon fibers in both the peripheral and the central branches of DRG ( Fig. 3 B  and C) . We observed no GFP + glial cells in DRGs and only a few faintly GFP + interneurons within the gray matter of the spinal cord, consistent with the reported tissue tropism of AAV (23) . The rostral spread of the virus was limited to the cervical spinal cord, because GFP was not detected in the brain (Fig.  S3A) . GFP expression was first visible at day 7 and was sustained at 28 d after injection (Fig. S3C) .
We first asked whether DRG neurons from the AAV-BMPinjected mice have enhanced axon growth potential. We chose to test BMP4 in this study, because in our previous work intraganglionic injection of BMP4 enhanced axonal growth (15) . The DRG neurons isolated from the AAV-BMP4-treated adult mice indeed extended much longer axons at 20 h than controls (Fig. 3 D and E). BMP4 expression was markedly increased, driven by AAV-mediated overexpression, and pSmad1 accumulated in the nuclei of DRG neurons in AAV-BMP4 mice (Fig. 3F ). In agreement with BMP4 being a secreted ligand, we observed a "field effect" from overexpression of BMP4: in AAV-BMP4 mice the percentage of the lumbar DRG neurons that had nuclear pSmad1 was much higher than the AAV transduction rate. Remarkably, GAP-43 was induced in DRGs from AAV-BMP4 mice, as in conditioned DRGs. In contrast, ATF3, another regeneration-associated gene (24), was not induced (Fig. 3F ). There were no detectable changes in the cellular components of the DRGs among treatment groups by histological analysis or cell type-specific markers (Fig. S3D ).
Sensory Axon Regeneration by Activation of the BMP Pathway in a
Mouse Model of SCI. Next, we tested AAV-BMP4 in a mouse SCI model of complete dorsal column transection (Fig. 4 A and B and Fig. S4A ). Mice were first injected with intrathecal AAV and 2 wk later received a T8 dorsal hemisection, thus allowing sufficient time for BMP4 overexpression to prime the DRG neurons. Regenerating axons were visualized by transganglionic labeling with Dextran-Texas Red (DexTR). In the control groups-sham, intrathecal saline, or AAV-GFP injection-at 2 wk after SCI, virtually all ascending fibers in the fasciculus gracilis had retracted from the caudal border of the lesion (Fig. 4 C-E, H, and I), consistent with the failure of regeneration in the CNS (25) . In contrast, in the AAV-BMP4 group, regenerative responses were observed (Fig. 4 F and J-M and Fig. S5E ). Significantly more injured fibers penetrated the caudal border of the lesion site, traversed the lesion epicenter, and even emerged from the rostral border (Fig. 4G) . Most regenerating fibers tended to remain in bundles, ascending dorsally into the scar, and then renegotiated their passage back to deeper portions of the dorsal column. Thus, the regenerating axons have characteristic circuitous trajectories along the ventral-dorsal axis (Fig. 4 L and M, arrows) , as opposed to the straight caudal-to-rostral trajectories of uninjured axons (Fig. 4 H and I) . Another salient feature of the regenerating axons was the frequent dye-filled swellings at the axon tips, which resembled growth cone-like structures (Fig. 4 L and M, arrowheads,  and Fig. S5 ). Lesion completeness was confirmed in every animal by the absence of tracer on cross-sections of rostral cervical spinal cord (Fig. S4) . Sometimes microcysts developed in the lesion core, and large bundles of regenerating fibers grew along the cyst wall and extended further rostrally (Fig. 4L) .
Confocal imaging revealed that regenerating axons tended to avoid high-density GFAP + areas and chose to navigate the less dense GFAP + areas (Fig. S5 ), in agreement with the model that reactive astrocytes secrete inhibitory extracellular molecules, such as chondroitin sulfate proteoglycans (CSPG) (26) . The promoting effect most likely resulted from an enhanced intrinsic growth potential, because only DRG neurons were selectively targeted by AAV with our intrathecal delivery method. In fact, injection of AAV-GFP into the lumbar intrathecal space ei-ther before or after SCI, or directly into the injury site at T8 spinal level, did not lead to GFP fluorescent signals in other cell types (Fig. S4 H-M) . Moreover, the scar size determined by fibronectin immunostaining seemed to be comparable among all experimental groups, and the neuronal populations near the scar appeared normal (Fig. S4N) .
The AAV-BMP4-injected animals displayed normal body weight, normal locomotion, intact grab reflex of hindpaws, and no aberrant somatosensory perceptions when tested for paw withdrawal to pain or light touch. A calibrated von Frey filament test further confirmed that there were no tactile perceptual abnormalities in the AAV groups, whereas severe mechanical allodynia was observed in control mice that received left sciatic nerve ligation (Fig. 5A) . CD45, a pan-leukocyte marker, was used to reveal the extent of infiltration of macrophages or other inflammatory cells, and we detected no observable differences in the DRGs from AAV-BMP-injected animals compared with the control groups (Fig. 5B) . Therefore, inflammatory or other side effects from the intrathecal AAV delivery seem minimal. Furthermore, the promoting effect of the AAV-BMP4 seems not to be related to the inflammation-triggered enhancement of the axon growth potential (27, 28) . We further asked whether a post-SCI injection of AAV-BMP4 would be sufficient to stimulate axonal regeneration, which represents a clinically relevant scenario. Animals received AAV-BMP4 injection 15 min after T8 SCI in the same anesthesia setting to avoid adverse effects from multiple sessions of anesthesia in a short period. Notably, we observed similar axonal regrowth in these animals ( Fig. 5 C-J) . Therefore, AAV-BMP4 delivered shortly after SCI is sufficient to switch DRG neurons into an active growth state to overcome early stages of gliosis. Step 1: intrathecal AAV injection.
Step 2: T8 dorsal hemisection at week 2.
Step 3: tracing of ascending sensory axons with DexTR at week 4. (C-F) Sagittal sections: rostral is to the left and caudal to the right. Lesion borders were defined by GFAP staining of the reactive astrocytes (blue) and marked with dashed white line, and asterisks denote the lesion center. In sham, saline, or AAV-GFP mice, DexTR + axons had retracted from the caudal border of the lesion site. In AAV-BMP4 mice, bundles of DexTR + axons had penetrated the lesion site, and some traversed the lesion epicenter and emerged from the rostral border. (G) There were significantly more axons closer to the lesion center in AAV-BMP4 mice than controls. Axon index is the ratio of the DexTR + axon number at a specific location relative to the axon number at the most caudal point-100% at >−0.4 mm. Data are shown as mean ± SEM. **P < 0.001, ***P < 0.0001, two-way ANOVA with Bonferroni post hoc correction. decision to form neural ectoderm to patterning and proliferation of the spinal cord (reviewed in ref. 29) . Smad has also been implicated in mediating BMP signaling from axon terminals, through retrograde transport, to regulate spatial patterning of neurons (30) . Here we propose a role of the BMP/Smad1 pathway in mediating axonal growth during CNS and PNS development. pSmad1 accumulates in the nuclei of neurons during axonogenesis. The initiation and the elongation of neurite outgrowth of both CNS and PNS neurons require BMP signaling. Exogenous BMP stimulation enhances axon growth potential. As neurons mature, the axon growth capability is diminished, coinciding with the decrease of nuclear pSmad1 in older neurons. A conditioning lesion induces and activates Smad1 in adult DRG neurons and increases the axon growth potential. Therefore, a conditioning lesion recapitulates, at least in part, the developing process of axon growth. Indeed, blocking BMP signaling in adult DRG neurons by pharmacological inhibition, genetic ablation of Smad1, or acute Smad1 knockdown by RNAi all lead to failure of initiation of axonal outgrowth or arrest of axonal elongation, whereas reactivating Smad1 signaling in adult DRG neurons in vivo by AAV-BMP4 results in induction of regeneration markers and rekindling of axon growth potential.
A large number of growth factors and guidance molecules, such as neurotrophins, netrin, and Wnts, are able to enhance axonal outgrowth (31) . Our results now add another classic signaling pathway to the growing family of growth factors that can mediate axon growth. Interestingly, Smad1 can act as a converging node integrating various signaling pathways through its linker phosphorylation at multiple MAPK and GSK3 phosphorylation sites. For example, in Xenopus embryos, dorsoventral (BMP) and anteroposterior (Wnt/GSK3) patterning gradients are integrated at the Smad1 linker area (32) . By analogy, BMP and NGF signaling pathways may also converge on Smad1 through differential phosphorylation to mediate axon growth.
Although we have focused here on the role of Smad1-dependent BMP signaling in axon growth, our results do not exclude functions of BMPs at the tips of axons, independent of nuclear signaling. Indeed, noncanonical BMP signaling pathways have been implicated in mediating local effects of BMPs-regulating actin dynamics in dendritogenesis (19) , acute growth cone collapse (33) , and synaptic stability (18) .
Activation of Smad1 Promotes Axonal Regeneration in SCI.
Our studies show that empowering adult neurons by increasing BMP signaling in vivo can enhance axon growth potential, thereby promoting axon regeneration in a mouse model of SCI. The phenotype could in part be caused by a lack of axonal dieback of neurons with AAV-BMP4 treatment, as has been shown in conditioned adult neurons (34, 35) . However, there seems to be genuine axonal regrowth: some axons did extend further rostrally, beyond the transection site, and even emerged from the rostral border of the lesion site. In addition, we observed a similar axonal regrowth phenotype when AAV-BMP4 was injected after SCI, in which case sufficient BMP4 was expressed after the acute axon dieback had occurred. Thus, besides potentially preventing acute axonal dieback, AAV-BMP4 mostly likely can also counteract the typical abortive attempt of axonal regeneration. The regeneration phenotype of AAV-BMP4 seems to be comparable to and, in some cases, even slightly more robust than the conditioning lesion in our mouse model of SCI, implying that AAV-BMP4 may not be simply a recapitulation of a conditioning lesion and that BMP4 may have recruited other signaling molecules beyond those activated by the conditioning lesion. In fact, BMP4 expression level with AAV-BMP was much higher than in conditioned DRGs (Fig. 3F) , thus neurons may be stimulated by BMP4 with greater magnitude and longer duration. In addition, as a secreted ligand, BMP4 may affect not only transduced DRG neurons but also neighboring nontransduced neurons through a paracrine fashion.
Although previous studies have shown that manipulation of the BMP pathway locally at the injury site affects astrogliosis (36) and may inhibit regeneration (37) , our studies activated the BMP/ Smad1 pathway directly in sensory neurons within DRG, thus demonstrating that enhancing neuronal intrinsic axon growth potential can be used as a strategy to promote axon regeneration in vivo. Our AAV-based in vivo gene delivery method selectively targeting DRG neurons is minimally invasive, clinically applicable, and represents a versatile experimental manipulation for SCI research. This is in contrast to other manipulations, such as intraganglionic injection of cAMP (38, 39) or an inflammatory agent, zymosan (27, 28) , both of which are not clinically feasible. Our AAV intrathecal injection is also an approach devoid of unwanted abnormalities in mechanosensation or pain perception, thus providing the basis for future translation into clinical treatment.
AAV-BMP4 injected immediately after the SCI still leads to sensory axon regeneration. Reportedly, glial and fibrous scars begin to form 1 wk after injury and further mature until 3 wk after injury (40) . This is consistent with prior observations that animals that received a peripheral axotomy concomitant with a central lesion show some degree of regeneration, whereas animal that received peripheral axotomy 2 wk after the SCI show no regeneration (41) , implying that the first 2 wk might be a window of opportunity for treatment. We based our time estimate of 7 d for the onset of transgene expression on the observation that GFP becomes visible at day 7; however, because we did not use GFP antibody to enhance detection sensitivity, transgene expression might have earlier onset. Apparently, the low level of BMP4 in the first few days after AAV injection is sufficient to switch DRG neurons into an active growth state. Because the initiation of the AAV transgene expression is on the order of days, not hours, we predict that AAV-BMP delivered a few hours or 1 d after the SCI-a more practical regimen for treating acute SCIshould have similar promoting effects as when AAV-BMP4 was injected 15 min after SCI. Future studies will explore whether AAV-BMP is effective for subacute or even chronic SCI. A selfcomplementary recombinant AAV8 (sc-rAAV8, engineered to be double stranded) with faster onset of transgene expression (23) might be crucial to rejuvenate neurons before astroglial scars become an impenetrable barrier for regeneration. Combinatorial strategies, such as relieving inhibition from CSPGs (42), cell grafting, or placement of growth factor gradients or guidance cues beyond lesion epicenter (43, 44) , might lead to synergistic effects. In fact, a time course study at 4 wk after SCI showed no further regeneration beyond the 2 wk after lesion, highlighting the importance of combinatorial strategies.
Future studies will also determine the therapeutic potential of AAVs encoding other subtypes of BMPs (in particular, BMP7, which has an enhancing effect on embryonic neurons, as shown in Fig. 1O ) or other components of the BMP signaling pathway for sensory axon regeneration. In addition, BMP signaling for the regeneration of motor fibers in the corticospinal tract (CST) can be readily tested: our pilot experiment demonstrated a similar decline of the pSmad1 in mature cortical motor neurons. The role of the Smad1/BMP4 pathway in the normal axonal regeneration of peripheral nerve after injury also awaits future studies.
Smad1 has also been found to be increased in cortical neurons that sprout a new connection after stroke as part of the neuronal growth program identified as "sprouting transcriptome" (45) . Additionally, BMP7 infusion has neuroregenerative effects after stroke (46) , suggesting that the promoting effect of BMP/Smad1 signaling is not limited to SCI. Taken together, we have found an essential role of the BMP/ Smad1 pathway in axonogenesis during development and in rekindling the innate growth potential in adult sensory neurons (Fig. 6) . Importantly, we discovered a promoting effect of AAV-BMP4 in the regeneration of long-projection sensory fibers in a rodent model of SCI. Modulating the BMP/Smad1 pathway thus represents a therapeutic strategy for axonal regeneration.
Materials and Methods
Mice, Conditioning Lesion, and Thoracic Dorsal Hemisection. All surgeries were performed on adult female mice 4-6 wk old in accordance with the guidelines and protocols approved by the Institutional Animal Care and Use Committee at the Mount Sinai School of Medicine. For the SCI model, C57BL/6 mice were used. Mice received ketamine and xylazine for anesthesia. Dorsal column transection injuries were performed as previously described (38, 41) . Briefly, the lamina of T8 spinal segment was exposed and the dorsal columns transected bilaterally using iris microscissors (Fine Science Tools), with the depth reaching ≈0.8 mm. For the peripheral conditioning lesion, the right sciatic nerve was exposed at midthigh level and transected. ).
AAV and Intrathecal Injection. For AAV preparation, cDNA of BMP4 or GFP was inserted downstream of a CMV promoter in a recombinant AAV8.2 vector (Virovek). Viral titers were on the order of 1 × 10 13 viral genomes per milliliter (vg/mL). Intrathecal injection was after the modified Wilcox technique (47) . The site of injection was between lumbar levels L5 and L6, a location where the spinal cord ends and the cauda equina begins in mouse. Specifically, a small laminectomy was performed to expose the thecal sac between L5 and L6. AAV particles on the order of 10 10 vg in 3-μL volume were injected using a 10-μL Hamilton syringe with a 32-gauge needle. To avoid injury to the underlying neural tissue, the needle remained at midline and was slowly inserted underneath the dura and further advanced in the subarachnoid space. The technical parameters, such as isotonic diluent, low-infusion pressure, and a small injection volume, were all consistent with the clinical practice of intrathecal drug delivery. After the injection, the paraspinal muscles and fascia were reapproximated with 5-0 chromic sutures and skin with staples. Mice then received 0.5 mL normal saline and were returned to a warm chamber for postoperative recovery. For sham surgery, only laminectomy was performed, with no dural breachment. At least five mice were used for each experimental group. For AAV injection, experiments were repeated at least twice.
Labeling of Ascending Sensory Axons in the Fasciculus Gracilis. The ascending sensory fibers in the fasciculus gracilis was labeled unilaterally with Texas Red-conjugated Dextran 3000 MW (DexTR; Invitrogen) 3 d before perfusion. The right sciatic nerve was exposed and crushed with forceps. DexTR (2.5μL) was injected into the sciatic nerve using a Hamilton syringe at the crush site.
Statistical Analysis. Prism Graphpad software was used to perform Student t test, one-way ANOVA, or two-way ANOVA, followed by Bonferroni's post hoc test with multiple comparisons. Data are presented as mean ± SEM.
